17-02-2020
Pavel Kapysh / Shutterstock.com
Indian drugmaker Zydus Cadila has launched a fast track programme to develop a vaccine for the novel coronavirus COVID-19, which has so far claimed more than 1,600 lives worldwide.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Zydus Cadila, COVID-19, Zydus Group, Pankaj Patel, SARS, coronavirus, vaccine, Johnson & Johnson, Janssen
India regulator U-turns on controversial generics-only policy
31-08-2023
India calls for IP waiver to combat COVID-19
02-03-2021
India approves COVID-19 vaccines ahead of huge rollout
05-01-2021
Sanofi announces new vaccine project as Australia begins animal tests
02-04-2020
Novartis and others in ‘unprecedented’ COVID-19 partnership
27-03-2020
Sanofi partners with HHS to work on COVID-19 vaccine
19-02-2020
J&J, HHS sign expanded deal to find COVID-19 vaccine
14-02-2020
